Endocine™, N3OA and N3OASq; Three Mucosal Adjuvants That Enhance the Immune Response to Nasal Influenza Vaccination

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Falkeborn, Tina ^a   Bråve, Andreas ^b   Larsson, Marie ^a   Åkerlind, Britt ^a   Schröder, Ulf ^c   Hinkula, Jorma ^a,c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Swedish Institute for Communicable Disease Control   (Sweden)

^c Eurocine Vaccines AB Karolinska Science Park   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOCINE; ENDOCINE ADJUVANT; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 2; N3 OLEYLAMINE ADJUVANT; N3 OLEYLAMINE SQUALENE ADJUVANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPOTENTIATION; INFLUENZA A; INFLUENZA VACCINATION; MUCOSAL IMMUNITY; NONHUMAN; T CELL DEPLETION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED;

EID: 84881332718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070527     Document Type: Article

References (61)

1. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, et al. (1998) Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 178: 53-60.
2. WHO. Influenza (Seasonal). 2012 [cited 2012 November 21]; Available: http://www.who.int/mediacentre/factsheets/fs211/en/index.html.
3. Farnsworth A, Cyr TD, Li C, Wang J, Li X, (2011) Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 29: 1529-1533.
4. van den Brand JM, Kreijtz JH, Bodewes R, Stittelaar KJ, van Amerongen G, et al. (2011) Efficacy of vaccination with different combinations of MF59-adjuvanted and nonadjuvanted seasonal and pandemic influenza vaccines against pandemic H1N1 (2009) influenza virus infection in ferrets. J Virol 85: 2851-2858.
5. Greenbaum E, Furst A, Kiderman A, Stewart B, Levy R, et al. (2002) Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine. Vaccine 20: 1232-1239.
6. Kuno-Sakai H, Kimura M, Ohta K, Shimojima R, Oh Y, et al. (1994) Developments in mucosal influenza virus vaccines. Vaccine 12: 1303-1310.
7. Quan FS, Compans RW, Nguyen HH, Kang SM, (2008) Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 82: 1350-1359.
8. Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, et al. (2008) A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26: 3352-3361.
9. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, et al. (2008) Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 105: 1644-1649.
10. Tamura S, Funato H, Hirabayashi Y, Kikuta K, Suzuki Y, et al. (1990) Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. Vaccine 8: 479-485.
11. Tamura S, Funato H, Hirabayashi Y, Suzuki Y, Nagamine T, et al. (1991) Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules. Eur J Immunol 21: 1337-1344.
12. Ambrose CS, Wu X, Jones T, Mallory RM, (2012) The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine 30: 6794-6801.
13. Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, et al. (2009) Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 83: 5726-5734.
14. Rowcliffe E, Bolmstedt A, Biller M, Wahren B, Olofsson S, et al. (2004) Demonstration of neutralizing mucosal IgA response to intranasal HIV-1 env DNA vaccines with or without the V3 glycosylation site. Scand J Infect Dis 36: 360-364.
15. Asakura Y, Hinkula J, Leandersson AC, Fukushima J, Okuda K, et al. (1997) Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand J Immunol 46: 326-330.
16. Schroder U, Svenson SB, (1999) Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine 17: 2096-2103.
17. Devito C, Zuber B, Schroder U, Benthin R, Okuda K, et al. (2004) Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 173: 7078-7089.
18. Hinkula J, Devito C, Zuber B, Benthin R, Ferreira D, et al. (2006) A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 24: 4494-4497.
19. Petersson P, Hedenskog M, Alves D, Brytting M, Schroder U, et al. (2010) The Eurocine L3 adjuvants with subunit influenza antigens induce protective immunity in mice after intranasal vaccination. Vaccine 28: 6491-6497.
20. Ohlin M, Hinkula J, Broliden PA, Grunow R, Borrebaeck CA, et al. (1992) Human MoAbs produced from normal, HIV-1-negative donors and specific for glycoprotein gp120 of the HIV-1 envelope. Clin Exp Immunol 89: 290-295.
21. Korhonen MH, Brunstein J, Haario H, Katnikov A, Rescaldani R, et al. (1999) A new method with general diagnostic utility for the calculation of immunoglobulin G avidity. Clin Diagn Lab Immunol 6: 725-728.
22. World Health Organization (2011) Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: World Health Organization. xii, 139 p.
23. Mittelholzer CM, Brokstad KA, Pauksens K, Jonsson R, Brytting M, et al. (2006) Human cell lines used in a micro neutralization test for measuring influenza-neutralizing antibodies. Scand J Immunol 63: 257-263.
24. Brave A, Johansson U, Hallengard D, Heidari S, Gullberg H, et al. (2010) Induction of HIV-1-specific cellular and humoral immune responses following immunization with HIV-DNA adjuvanted with activated apoptotic lymphocytes. Vaccine 28: 2080-2087.
25. Applequist SE, Rollman E, Wareing MD, Liden M, Rozell B, et al. (2005) Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 175: 3882-3891.
26. Charo J, Lindencrona JA, Carlson LM, Hinkula J, Kiessling R, (2004) Protective efficacy of a DNA influenza virus vaccine is markedly increased by the coadministration of a Schiff base-forming drug. J Virol 78: 11321-11326.
27. Plotkin AS, Orenstein AW, Offit AP, editors (2008) Vaccines. 5th ed: Elsevier Inc.
28. Boyce TG, Hsu HH, Sannella EC, Coleman-Dockery SD, Baylis E, et al. (2000) Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine 19: 217-226.
29. Tyring SK (2006) Mucosal Immunology and Virology. Springer-Verlag London Ltd.
30. Renegar KB, Small PA Jr, Boykins LG, Wright PF, (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173: 1978-1986.
31. Sealy R, Webby RJ, Crumpton JC, Hurwitz JL, (2012) Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines. Int Immunol 25: 183-195.
32. Atassi MZ, Webster RG, (1983) Localization, synthesis, and activity of an antigenic site on influenza virus hemagglutinin. Proc Natl Acad Sci U S A 80: 840-844.
33. Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, et al. (2005) Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J Virol 79: 7380-7388.
34. Babon JA, Cruz J, Ennis FA, Yin L, Terajima M, (2012) A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus. J Virol 86: 9233-9243.
35. Tamura S, (2010) Studies on the usefulness of intranasal inactivated influenza vaccines. Vaccine 28: 6393-6397.
36. BLAST. Basic Local Alignment Search Tool. [cited 2013 May 28]; Available: http://blast.ncbi.nlm.nih.gov/Blast.cgi.
37. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
38. Skowronski DM, Hamelin ME, Janjua NZ, De Serres G, Gardy JL, et al. (2012) Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One 7: e38929.
39. Shen X, Lagergard T, Yang Y, Lindblad M, Fredriksson M, et al. (2000) Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine. Infect Immun 68: 5749-5755.
40. Shen X, Lagergard T, Yang Y, Lindblad M, Fredriksson M, et al. (2001) Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate. Vaccine 19: 3360-3368.
41. Zuercher AW, Coffin SE, Thurnheer MC, Fundova P, Cebra JJ, (2002) Nasal-associated lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune responses. J Immunol 168: 1796-1803.
42. Abbas AK, Lichtman AH, Pillai S (2003) Cellular and Molecular Immunology: Elsevier Science. 562 p.
43. Abbas AK, Lichtman AH, Pillai S (2011) Cellular and Molecular Immunology. 7 ed. Philadelphia: ELSEVIER. 225-242.
44. (2011-10-26) Influenza Sequence & Epitope Database (ISED). Available: http://influenza.korea.ac.kr/ISED2/index_3.jsp.
45. Lawson CM, Bennink JR, Restifo NP, Yewdell JW, Murphy BR, (1994) Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol 68: 3505-3511.
46. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, et al. (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS One 5: e13162.
47. Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrom T, Agger EM, et al. (2010) Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release 145: 102-108.
48. Henriksen-Lacey M, Devitt A, Perrie Y, (2011) The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release 154: 131-137.
49. Marrack P, McKee AS, Munks MW, (2009) Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 9: 287-293.
50. Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, et al. (2001) Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 31: 2910-2918.
51. Calabro S, Tortoli M, Baudner BC, Pacitto A, Cortese M, et al. (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29: 1812-1823.
52. Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, et al. (2006) A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 24: 3990-4006.
53. Even-Or O, Joseph A, Itskovitz-Cooper N, Samira S, Rochlin E, et al. (2011) A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS). II. Studies in mice and ferrets and mechanism of adjuvanticity. Vaccine. 29: 2474-2486.
54. Even-Or O, Samira S, Rochlin E, Balasingam S, Mann AJ, et al. (2010) Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine. Vaccine 28: 6527-6541.
55. Davis SS, (2001) Nasal vaccines. Adv Drug Deliv Rev 51: 21-42.
56. Durrer P, Gluck U, Spyr C, Lang AB, Zurbriggen R, et al. (2003) Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21: 4328-4334.
57. Mizuno D, Kimoto T, Takei T, Fukuta A, Shinahara W, et al. (2011) Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity. Vaccine 29: 5368-5378.
58. Christensen D, Korsholm KS, Andersen P, Agger EM, (2011) Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 10: 513-521.
59. Rappuoli R, Mandl CW, Black S, De Gregorio E, (2011) Vaccines for the twenty-first century society. Nat Rev Immunol 11: 865-872.
60. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, et al. (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 3: 85ra48.
61. O'Hagan DT, Ott GS, De Gregorio E, Seubert A, (2012) The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30: 4341-4348.